Department of Epidemiology and Biostatistics, University of California, San Francisco.
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco.
JAMA Intern Med. 2022 Oct 1;182(10):1025-1034. doi: 10.1001/jamainternmed.2022.3355.
Self-measured blood pressure (SMBP) with commercially available connected smartphone applications may help patients effectively use SMBP measurements.
To determine if enhanced SMBP paired with a connected smartphone application was superior to standard SMBP for blood pressure (BP) reduction or patient satisfaction.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted among 23 health systems participating in PCORnet, the National Patient-Centered Clinical Research Network, and included patients who reported having uncontrolled BP at their last clinic visit, a desire to lower their BP, and a smartphone. Enrollment and randomization occurred from August 3, 2019, to December 31, 2020, which was followed by 6 months of follow-up for each patient. Analysis commenced shortly thereafter.
Eligible participants were randomly assigned to enhanced SMBP using a device that paired with a connected smartphone application (enhanced) or a standard device (standard). Participants received their device in the mail, along with web-based educational materials and phone-based support as needed. No clinician engagement was undertaken, and the study provided no special mechanisms for delivering measurements to clinicians for use in BP management.
Reduction in systolic BP, defined as the difference between clinic BP at baseline and the most recent clinic BP extracted from electronic health records at 6 months.
Enrolled participants (1051 enhanced [50.0%] vs 1050 standard [50.0%]; 1191 women [56.7%]) were mostly middle-aged or older (mean [SD] age, 58 [13] years), nearly a third were Black or Hispanic (645 [31%]), and most were relatively comfortable using technology (mean [SD], 4.1 [1.1] of 5). The mean (SD) change in systolic BP from baseline to 6 months was -10.8 (18) mm Hg vs -10.6 (18) mm Hg (enhanced vs standard: adjusted difference, -0.19 mm Hg; 95% CI, -1.83 to 1.44; P = .81). Secondary outcomes were mostly null, except for documented attainment of BP control to lower than 140/<90 mm Hg, which occurred in 32% enhanced vs 29% standard groups (odds ratio, 1.15; 95% CI, 1.01-1.34). Most participants were very likely to recommend their SMBP device to a friend (70% vs 69%).
This randomized clinical trial found that enhanced SMBP paired with a smartphone application is not superior to standard SMBP for BP reduction or patient satisfaction.
ClinicalTrials.gov Identifier: NCT03796689.
使用商业上可用的带智能手机应用程序的自我测量血压(SMBP)可能有助于患者有效地使用 SMBP 测量。
确定增强型 SMBP 与智能手机应用程序配对是否优于标准 SMBP 来降低血压或提高患者满意度。
设计、地点和参与者:这项随机临床试验是在参与 PCORnet(国家以患者为中心的临床研究网络)的 23 个卫生系统中进行的,包括在上一次就诊时报告血压未得到控制、希望降低血压且拥有智能手机的患者。招募和随机分组于 2019 年 8 月 3 日至 2020 年 12 月 31 日进行,随后对每位患者进行了 6 个月的随访。分析随后不久开始。
符合条件的参与者被随机分配到使用与智能手机应用程序配对的设备(增强型)或标准设备(标准型)的增强型 SMBP。参与者通过邮件收到设备,同时还提供了基于网络的教育材料和按需提供的电话支持。没有临床医生的参与,该研究也没有提供将测量值特殊机制传递给临床医生以用于血压管理。
收缩压降低,定义为基线时诊所血压与 6 个月时从电子健康记录中提取的最近诊所血压之间的差异。
纳入的参与者(增强组 1051 名[50.0%],标准组 1050 名[50.0%];1191 名女性[56.7%])年龄大多在中年或以上(平均[标准差]年龄 58[13]岁),近三分之一是黑人和西班牙裔(645[31%]),大多数人对使用技术相对舒适(平均[标准差],4.1[1.1]分中的 5 分)。从基线到 6 个月时的收缩压平均(标准差)变化为-10.8(18)mm Hg 与-10.6(18)mm Hg(增强型与标准型:调整后的差值,-0.19 mm Hg;95%置信区间,-1.83 至 1.44;P = 0.81)。次要结果大多为零,除了记录到的血压控制到低于 140/<90 mm Hg,增强组为 32%,标准组为 29%(优势比,1.15;95%置信区间,1.01-1.34)。大多数参与者非常愿意向朋友推荐他们的 SMBP 设备(70%对 69%)。
这项随机临床试验发现,增强型 SMBP 与智能手机应用程序配对并不优于标准 SMBP 来降低血压或提高患者满意度。
ClinicalTrials.gov 标识符:NCT03796689。